Health Care

Revised Potential Distribution Range of $0.03 to $0.07 per share
based on current estimates and assumptions

PHILADELPHIA and VANCOUVER, British Columbia, July 16, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its best-efforts public offering of 12,000,000 units. Each unit consists of one common share (or one pre-funded warrant (“Pre-Funded Warrant”) in lieu thereof) and one warrant (the “Warrants”). Each unit was sold to the public at a price of $1.25 per unit (inclusive of the Pre-Funded Warrant exercise price) for gross proceeds of $15 million, before deducting placement agent fees and offering expenses. Each Pre-Funded Warrant is exercisable to purchase one common share at an exercise price of $0.001 until such time as the Pre-Funded Warrant is exercised in full and each Warrant is immediately exercisable, and entitles the holder thereof to purchase one common share at an exercise price of $1.50 per share for a period of five years from the date of issuance. The common shares (or Pre-Funded Warrants) and Warrants were purchased together in the offering but were issued separately.

GERMANTOWN, Md., July 16, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its second quarter 2025 financial results after market close on Wednesday, August 6, 2025.

Discover how CrazyBulk’s natural legal steroids are transforming muscle building supplements for bodybuilding women seeking safe, effective female muscle growth.

Half-Year Report on Liquidity Contract with Invest Securities

ALBUQUERQUE, New Mexico, July 16, 2025 (GLOBE NEWSWIRE) -- As the medical aesthetics industry continues to experience exponential growth, many medspa owners and aesthetic providers find themselves overwhelmed — juggling clients, marketing, operations, and still struggling to generate consistent profits. Dr. Kalpana Sundar, a board-certified physician and nationally recognized aesthetic business strategist, is on a mission to change that. This August, she is bringing her signature Aesthetic Profit Accelerator Bootcamp to Albuquerque, New Mexico, from August 7–10, 2025 — a powerful four-day intensive seminar designed to help aesthetic professionals turn passion into predictable, scalable profit.

SUNNYVALE, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that Henry Ford Health in Detroit, Michigan is now enrolling patients with ischemic HFrEF in the Company’s ongoing pivotal CardiAMP HF II trial.